You just read:

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First-Line Therapy in Patients with Endometrial or Squamous Lung Cancer

News provided by

Ability Pharmaceuticals SL

22 Nov, 2016, 09:30 ET